Equities

Cipher Pharmaceuticals Inc

Cipher Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CAD)17.89
  • Today's Change0.26 / 1.47%
  • Shares traded50.92k
  • 1 Year change+317.99%
  • Beta1.1753
Data delayed at least 15 minutes, as of Oct 11 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

  • Revenue in CAD (TTM)30.44m
  • Net income in CAD31.06m
  • Incorporated2020
  • Employees9.00
  • Location
    Cipher Pharmaceuticals Inc5750 Explorer Drive,, Suite 404MISSISSAUGA L4W 0A9CanadaCAN
  • Phone+1 (905) 602-5840
  • Websitehttps://www.cipherpharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Arch Biopartners Inc1.38m-2.57m119.86m--------86.62-0.0409-0.04090.0221-0.10210.9363--1.88---174.05-214.82---------185.89-180.45---3.57----105.63---136.30------
Biosyent Inc33.82m7.15m125.26m0.0017.703.4716.443.700.59880.59882.833.060.83521.347.74--17.6614.7720.1616.9279.7779.7421.1419.994.90--0.03099.2613.127.9718.352.52-2.67--
Spectral Medical Inc1.90m-18.35m161.11m29.00------84.75-0.0657-0.06630.0068-0.08120.23174.243.4865,551.73-223.64-109.65---175.3537.6163.74-965.02-445.720.5867-2.81-----4.14-16.08-104.12--31.53--
Aurora Cannabis Inc278.68m-29.77m400.14m1.07k--0.7123--1.44-0.6054-0.66835.8910.280.33361.738.83259,723.20-4.00---5.11---1.16---12.00--2.03--0.1449--------------
Cipher Pharmaceuticals Inc30.44m31.06m452.09m9.0014.313.4813.8714.851.231.231.225.060.25391.464.623,382,695.0025.9021.5328.3527.4081.0883.58102.0157.3110.59--0.00330.002.36-1.44-23.4876.18-53.51--
Knight Therapeutics Inc337.87m-21.23m583.09m725.00--0.765119.651.73-0.2087-0.20873.277.530.34491.723.58466,033.10-2.170.3477-2.450.415648.3746.28-6.281.692.430.22110.07080.0011.8092.2443.68--20.79--
Canopy Growth Corp287.10m-602.30m657.27m1.03k--0.8299--2.29-7.53-9.583.556.580.16521.754.22279,008.80-34.65-26.08-41.36-28.6731.062.59-209.79-333.291.64-0.29570.5392---10.835.5984.29---64.60--
Cronos Group Inc139.83m-78.83m1.11bn626.00--0.7644--7.97-0.2067-0.20690.36663.810.09012.297.09---5.136.43-5.267.1116.37-10.54-56.97147.0727.41--0.00--0.567248.4054.99---50.99--
Data as of Oct 11 2024. Currency figures normalised to Cipher Pharmaceuticals Inc's reporting currency: Canadian Dollar CAD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.